ES2147729T3 - Dominios de la region extracelular de polipeptidos receptores de factor de crecimiento derivado de plaquetas humano. - Google Patents

Dominios de la region extracelular de polipeptidos receptores de factor de crecimiento derivado de plaquetas humano.

Info

Publication number
ES2147729T3
ES2147729T3 ES92906305T ES92906305T ES2147729T3 ES 2147729 T3 ES2147729 T3 ES 2147729T3 ES 92906305 T ES92906305 T ES 92906305T ES 92906305 T ES92906305 T ES 92906305T ES 2147729 T3 ES2147729 T3 ES 2147729T3
Authority
ES
Spain
Prior art keywords
growth factor
extracellular region
polypeptides
domains
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92906305T
Other languages
English (en)
Inventor
Jaime A Escobedo
Lewis T Williams
David Wolf
James E Tomlinson
Larry J Fretto
Neill A Giese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
COR Therapeutics Inc
Original Assignee
University of California
COR Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, COR Therapeutics Inc filed Critical University of California
Application granted granted Critical
Publication of ES2147729T3 publication Critical patent/ES2147729T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

SE PRESENTAN CONSTRUCCIONES DEFINIDAS DE POLIPEPTIDOS RECEPTORES DE FACTOR DE CRECIMIENTO DERIVADOS DE PLAQUETAS HUMANAS. SE PRESENTAN LAS ESTRUCTURAS DE CAMPO DE REGION EXTRACELULAR SE IDENTIFICAN Y LAS MODIFICACION Y REDISPOSICIONES COMBINATORIAS DE LOS SEGMENTOS RECEPTORES. TANTO EL ENLACE CELULAR CON LAS FORMAS SOLUBLES DE SEGMENTOS MODIFICADOS SE HACEN DISPONIBLES, AL SER METODOS PARA ENSAYOS QUE LOS UTILIZAN, PERMITIENDO EL FILTRADO O LOS ANALOGOS DE LIGANDOS.
ES92906305T 1991-01-31 1992-01-28 Dominios de la region extracelular de polipeptidos receptores de factor de crecimiento derivado de plaquetas humano. Expired - Lifetime ES2147729T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65079391A 1991-01-31 1991-01-31

Publications (1)

Publication Number Publication Date
ES2147729T3 true ES2147729T3 (es) 2000-10-01

Family

ID=24610314

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92906305T Expired - Lifetime ES2147729T3 (es) 1991-01-31 1992-01-28 Dominios de la region extracelular de polipeptidos receptores de factor de crecimiento derivado de plaquetas humano.

Country Status (13)

Country Link
US (3) US5686572A (es)
EP (1) EP0584082B1 (es)
JP (1) JPH06507543A (es)
AT (1) ATE193553T1 (es)
AU (2) AU1411092A (es)
CA (1) CA2100559C (es)
DE (1) DE69231128T2 (es)
DK (1) DK0584082T3 (es)
ES (1) ES2147729T3 (es)
GR (1) GR3034267T3 (es)
IE (1) IE920317A1 (es)
NZ (1) NZ241480A (es)
WO (1) WO1992013867A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013867A1 (en) * 1991-01-31 1992-08-20 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
IE920318A1 (en) * 1991-01-31 1992-07-29 Univ California Human platelet-derived growth factor receptors
US20020009443A1 (en) * 1991-12-02 2002-01-24 Vanitha Ramakrishman Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
PL171788B1 (pl) * 1991-12-02 1997-06-30 Cor Therapeutics Inc wykazujacego aktywnosc wiazania receptora ludzkiego czynnika wzrostupochodzacego z plytek PL PL PL
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US5776755A (en) * 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
EP1353952B1 (en) 1994-11-14 2007-04-11 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
US20040002117A1 (en) * 1998-02-12 2004-01-01 Hogan Patrick G. Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases
WO2000021560A1 (en) 1998-10-09 2000-04-20 Ludwig Institute For Cancer Research Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY
NZ516258A (en) * 1999-06-07 2004-02-27 Immunex Corp Tek antagonists
US6667173B2 (en) 2000-12-01 2003-12-23 The Schepens Eye Research Institute Nucleic acids encoding platelet derived growth factor-alpha receptors
WO2003105773A2 (en) 2002-06-01 2003-12-24 Oregon Health & Science University Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets:
US20050239088A1 (en) * 2003-05-16 2005-10-27 Shepard H M Intron fusion proteins, and methods of identifying and using same
EP2281885A1 (en) 2003-08-27 2011-02-09 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
JP2008506366A (ja) * 2004-05-14 2008-03-06 レセプター バイオロジックス インコーポレイテッド 細胞表面受容体アイソフォームならびにその同定および使用方法
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
US8128929B2 (en) 2005-06-17 2012-03-06 Imclone Llc Antibodies against PDGFRa
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
NZ579734A (en) * 2007-04-17 2012-01-12 Imclone Llc Platelet derived growth factor receptor-beta antibodies
WO2008142165A1 (en) * 2007-05-24 2008-11-27 Ablynx N.V. Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
JP2010529127A (ja) 2007-06-05 2010-08-26 イエール ユニバーシティ 受容体型チロシンキナーゼの阻害物質およびその使用方法
AU2009228158B2 (en) 2008-03-27 2014-02-27 Zymogenetics, Inc. Compositions and methods for inhibiting PDGFRbeta and VEGF-A
JP2012518657A (ja) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー 併用抗癌治療
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
JP2013531679A (ja) 2010-07-02 2013-08-08 メディミューン，エルエルシー 抗体製剤
EP2668210B1 (en) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
BR112015001459B1 (pt) 2012-07-25 2023-02-14 Celldex Therapeutics, Inc Anticorpo isolado ou fragmento do mesmo, conjugado, usos dos mesmos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, célula isolada, kit, método in vitro para inibir atividade da kit, método para produzir um anticorpo
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
CA2901226C (en) 2013-02-18 2020-11-17 Vegenics Pty Limited Vascular endothelial growth factor binding proteins
HUE060464T2 (hu) 2013-03-13 2023-03-28 Genzyme Corp PDGF- és VEGF-kötõrészeket tartalmazó fúziós fehérjék és eljárások azok alkalmazására
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
EP3145543A4 (en) 2014-05-23 2017-12-13 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6849590B2 (ja) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
KR20180104635A (ko) 2015-12-30 2018-09-21 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325224B1 (en) * 1988-01-22 1996-07-31 ZymoGenetics, Inc. Methods of producing secreted receptor analogs
AU607306B2 (en) * 1988-02-02 1991-02-28 Regents Of The University Of California, The Human platelet-derived growth factor receptor
EP0869177B1 (en) * 1989-02-09 2008-06-04 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Polyclonal antibody against the human alpha pdgf receptor and use thereof
IL97996A0 (en) * 1990-04-30 1992-06-21 Novo Nordisk As Hybrid cellular receptor
WO1992013867A1 (en) * 1991-01-31 1992-08-20 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
IE920318A1 (en) * 1991-01-31 1992-07-29 Univ California Human platelet-derived growth factor receptors
PL171788B1 (pl) * 1991-12-02 1997-06-30 Cor Therapeutics Inc wykazujacego aktywnosc wiazania receptora ludzkiego czynnika wzrostupochodzacego z plytek PL PL PL
PL171920B1 (pl) * 1991-12-02 1997-06-30 Cor Therapeutics Inc Sposób wytwarzania nowego, hamujacego PDGF-R polipeptydy immunoglobulinowego PL

Also Published As

Publication number Publication date
US5686572A (en) 1997-11-11
ATE193553T1 (de) 2000-06-15
NZ241480A (en) 1993-09-27
DE69231128D1 (de) 2000-07-06
GR3034267T3 (en) 2000-12-29
US5891652A (en) 1999-04-06
EP0584082A4 (en) 1994-08-24
WO1992013867A1 (en) 1992-08-20
JPH06507543A (ja) 1994-09-01
AU5580496A (en) 1996-09-19
DK0584082T3 (da) 2000-10-16
EP0584082A1 (en) 1994-03-02
AU709177B2 (en) 1999-08-26
DE69231128T2 (de) 2001-02-15
EP0584082B1 (en) 2000-05-31
AU1411092A (en) 1992-09-07
IE920317A1 (en) 1992-07-29
CA2100559A1 (en) 1992-08-01
CA2100559C (en) 2007-05-22
US5872218A (en) 1999-02-16

Similar Documents

Publication Publication Date Title
ES2147729T3 (es) Dominios de la region extracelular de polipeptidos receptores de factor de crecimiento derivado de plaquetas humano.
ATE480252T1 (de) Peptidantagonist von zonulin und dessen verwendung
DE69837473D1 (de) Verwendung von antagonisten der zentralen kannabinoidrezeptoren zur regulierung von suchterscheinungen
MX9604316A (es) Anticuerpos agonistas de la proteina tirosina cinasa.
DK0529065T3 (da) Receptorbaserede fremgangsmåder til screening for amylinagonister og -antagonister
ATE262040T1 (de) Methoden zur bestimmung der rezeptoraktivität und dafür verwendbare konstrukte
ATE225670T1 (de) Antagonistische anti-avb3 integrin antikörper
NO991162D0 (no) Monoklonale antistoffer mot det ekstracellulµre domene av humant VEGF-reseptorprotein (KDR)
ATE226247T1 (de) Menschliche neuronale nikotin-acetylcholin- rezeptor-verbindungen und methoden ihres einsatzes
EA199900630A1 (ru) Антагонисты рецепторов витронектина
ATE201016T1 (de) Pyrimidindion-, pyrimidintrion-, triazindion- derivate als alpha-1-adrenergische rezeptorantagonisten
AU1208497A (en) Ligand polypeptides for the g-protein-coupled receptor protein, their production and use
AU4493393A (en) Expression vectors that produce steroid receptors, steroid receptor chimera, screening assays for steroid receptors and clinical assays using synthesized receptors and receptor vectors
ATE229036T1 (de) Il-8 inhibitoren
DE69938725D1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
ES2166462T3 (es) Antagonistas del receptor de la endotelina.
SE9701010D0 (sv) Antibody
DE69614701D1 (de) Synthetisches, poröses, kristallines mcm 61, dessen synthese und verwendung
DE58904019D1 (de) Enantiomere silane, modifiziertes traegermaterial und dessen verwendung.
DE59813016D1 (de) Cadherin derived growth factor und seine verwendung
ATE184286T1 (de) Hgpiib-fragmente und ihre verwendung in in-vitro- verfahren zur bestimmung von in vivo stattfindenden thrombotischen ereignissen
DE60032931D1 (de) Polypeptide aus den zellkernrezeptor des vitamins d, und ihre verwendung insbesondere zum screening von vitamin d-analoga
NO951250L (no) Amylin-antagonist og fremgangsmåte for screening derav
IT9006602A0 (it) Test immunoenzimatico per la ricerca e determinazione degli anticorpi anti-ss-dna.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 584082

Country of ref document: ES